Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan downgrades Centrica, cites limited valuation upside

(Sharecast News) - JPMorgan Cazenove downgraded British Gas owner Centrica on Monday to 'neutral' from 'overweight' and trimmed the price target to 167p from 170p, citing limited valuation upside. "Our analysis suggests that Centrica shares present a balanced risk/reward proposition and we therefore downgrade the stock to neutral," the bank said.

JPM noted that the shares have outperformed the sector by around 290% since 3Q 2020, where it argued that the market underappreciated the group's balance sheet strength as well as potential earnings upside from restructuring.

"With much of this now realised, and with the normalisation of commodity prices and volatility, we see more limited upside from here," it said.

The bank said its refreshed 2025/2026 earnings per share estimates are 11%/5% below Bloomberg median consensus.

"We expect interim results on July 24th to confirm that Energy Markets & Trading as well as UK Energy Retail market conditions remain challenging, although investors should see these conditions as one-off," JPM said.

At 1020 BST, the shares were down 1.6% at 160.90p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.